English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background and purpose  Depressed mood is a common psychiatric problem associated with Parkinson's disease ( PD ), and studies have suggested a benefit of rasagiline treatment.    Methods   ACCORDO  (see the [Appendix 1. Appendix ACCORDO co‐investigators were Monica Bandettini di Poggio, Paolo ...]) was a 12‐week, double‐blind, placebo‐controlled trial to evaluate the effects of rasagiline 1 mg/day on depressive symptoms and cognition in non‐demented  PD  patients with depressive symptoms. The primary efficacy variable was the change from baseline to week 12 in depressive symptoms measured by the Beck Depression Inventory ( BDI ‐ IA ) total score. Secondary outcomes included change from baseline to week 12 in cognitive function as assessed by a comprehensive neuropsychological battery; Parkinson's disease quality of life questionnaire ( PDQ ‐39) scores; Apathy Scale scores; and Unified Parkinson's Disease Rating Scale ( UPDRS ) subscores.    Results  One hundred and twenty‐three patients were randomized. At week 12 there was no significant difference between groups for the reduction in total  BDI ‐ IA  score (primary efficacy variable). However, analysis at week 4 did show a significant difference in favour of rasagiline (marginal means difference ±  SE : rasagiline −5.46 ± 0.73 vs. placebo −3.22 ± 0.67;  P  = 0.026). There were no significant differences between groups on any cognitive test. Rasagiline significantly improved  UPDRS  Parts I ( P  = 0.03) and  II  ( P  = 0.003) scores versus placebo at week 12.  Post hoc  analyses showed the statistical superiority of rasagiline versus placebo in the  UPDRS  Part I depression item ( P  = 0.04) and  PDQ ‐39 mobility ( P  = 0.007) and cognition domains ( P  = 0.026).    Conclusions  Treatment with rasagiline did not have significant effects versus placebo on depressive symptoms or cognition in  PD  patients with moderate depressive symptoms. Although limited by lack of correction for multiple comparisons,  post hoc  analyses signalled some improvement in patient‐rated cognitive and depression outcomes.

A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non‐demented Parkinson's disease patients